Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

Tumour necrosis factor-alpha inhibitors (TNFi) have revolutionized the treatment of moderate-to-severe psoriasis. Following patent expiry of the originator biologics, TNFi biosimilars became available, presenting the opportunity for significant reductions in drug costs. To describe the uptake of TNF...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of dermatology (1951) 2023-07, Vol.189 (1), p.62-70
Hauptverfasser:	Phan, Duc Binh, Bewley, Anthony P, Smith, Catherine H, Mackenzie, Teena, Griffiths, Christopher E M, Lunt, Mark, Warren, Richard B, Yiu, Zenas Z N
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - therapeutic use Adjuvants, Immunologic - therapeutic use Biosimilar Pharmaceuticals - therapeutic use Dermatologists Etanercept - therapeutic use Humans Immunologic Factors - therapeutic use Infliximab - therapeutic use Male Psoriasis - drug therapy Tumor Necrosis Factor-alpha
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!